Terms: = Endocrine gland cancer AND CBL, RNF55, 867, ENSG00000110395, C-CBL, CBL2 AND Clinical Outcome
3 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract] [Full Text] [Related]
3. Genetic and epigenetic characterization of posterior pituitary tumors.
Schmid S; Solomon DA; Perez E; Thieme A; Kleinschmidt-DeMasters BK; Giannini C; Reinhardt A; Asa SL; Mete O; Stichel D; Siewert C; Dittmayer C; Hasselblatt M; Paulus W; Nagel C; Harter PN; Schittenhelm J; Honegger J; Rushing E; Coras R; Pfister SM; Buslei R; Koch A; Perry A; Jones DTW; von Deimling A; Capper D; Lopes MB
Acta Neuropathol; 2021 Dec; 142(6):1025-1043. PubMed ID: 34661724
[TBL] [Abstract] [Full Text] [Related]
